GRA VentureLab company awarded $3 million from NIH to advance ischemia research

July 28, 2011 at 11:43 am Leave a comment

NeurOp, a biopharmaceutical GRA VentureLab company focused on treatments for central nervous systems disorders, has garnered $3 million from the NIH to further its ischemia research program.  Specifically, NeurOp will focus the funding on bringing its lead molecule forward to an Investigational New Drug filing for the treatment of subarachnoid hemorrhage and those patients at risk for stroke.

According to Barney Koszalka, Ph.D., NeurOp president and CEO, “This grant, coupled with support from the Georgia Research Alliance, will accelerate our work to identify within the year a drug candidate for ischemia to advance into pre-IND studies.”

Based on technology developed in the laboratories of  Ray Dingledine, Ph.D., at Emory University, NeurOp is developing treatments for depression, neuropathic pain, schizophrenia and Parkinson’s disease, in addition to ischemia.  Read more here>

Entry filed under: Commercialization/VentureLab, News.

GRA Eminent Scholar leads HIV/AIDS research consortium GRA VentureLab company Urjanet closes Series A financing at $2.2 million

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

Trackback this post  |  Subscribe to the comments via RSS Feed